Charles E. Triano | Pfizer Inc. |
Ian C. Read | Pfizer Inc. |
Frank A. D'Amelio | Pfizer Inc. |
Albert Bourla | Pfizer Inc. |
Mikael Dolsten | Pfizer Inc. |
Gregg Gilbert | Deutsche Bank Securities, Inc. |
Jami Rubin | Goldman Sachs & Co. LLC |
Chris Schott | JPMorgan Securities LLC |
Umer Raffat | Evercore ISI |
Vamil K. Divan | Credit Suisse Securities (NYSE:USA) LLC |
John T. Boris | SunTrust Robinson Humphrey, Inc. |
Alex Arfaei | BMO Capital Markets (United States) |
Andrew S. Baum | Citigroup Global Markets Ltd. |
Louise Chen | Cantor Fitzgerald Securities |
David R. Risinger | Morgan Stanley & Co. LLC |
Jason M. Gerberry | Bank of America Merrill Lynch |
Geoff Meacham | Barclays Capital, Inc. |
Good day everyone, and welcome to Pfizer's Second Quarter 2018 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Mr. Chuck Triano, Senior Vice President of Investor Relations. Please go ahead, sir.